scispace - formally typeset
E

Elena Nikiphorou

Researcher at King's College London

Publications -  263
Citations -  3444

Elena Nikiphorou is an academic researcher from King's College London. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 24, co-authored 172 publications receiving 1849 citations. Previous affiliations of Elena Nikiphorou include Leiden University Medical Center & New Cross Hospital.

Papers
More filters
Journal ArticleDOI

Nutrition and its role in prevention and management of rheumatoid arthritis.

TL;DR: In this paper , a review of the evidence relating RA risk and management with focus on specific foods such as fish and diets/dietary patterns such as the Mediterranean diet, fasting and elimination diets and oral nutritional supplements including omega-3 polyunsaturated fatty acids (PUFA).
Journal ArticleDOI

Rheumatoid Arthritis: Clinical Aspects [322–355]322. The Effect of Biologics on Cardiovascular Disease in Patients with Rheumatoid Arthritis: A Systematic Literature Review

Sarah L. Westlake, +123 more
- 01 Apr 2010 - 
Journal ArticleDOI

Basic science232. Certolizumab pegol prevents pro-inflammatory alterations in endothelial cell function

Sarah Heathfield, +482 more
- 01 May 2012 - 
TL;DR: It is found at a cellular level that a clinically available TNF inhibitor, CZP reduces the expression of adhesion molecule expression, and prevents TNF-induced activation of the NF-κB pathway.
Journal ArticleDOI

FRI0014 Examining Baseline and 1 Year Predictors of Radiographic Progression over 5 Years Using Mixed Effects Negative Binomial Models: Results from the Early Rheumatoid Arthritis Study (ERAS) Cohort

TL;DR: The rate of radiographic progression over 5 years increased significantly, following a linear function, and this is the first model to indicate the possible predictive power of HB and HAQ in the first years of disease.
Journal ArticleDOI

AB1172 Biologic DMARD Treatment in Cyprus Based on Six Year Data from a National Hospital Covering a Population of Greek-Cypriot

TL;DR: Etanercept was found to be generally well tolerated in AS and PsA, with patients adhering to treatment whereas in the case of RA infliximab was poorly tolerated and adhered to in the majority of patients.